Author： Scheen André J.
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.33, Iss.7, 2010-07, pp. : 615-618
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Cardiovascular Risk-Benefit Profile of Sibutramine
By Scheen A.J.
American Journal of Cardiovascular Drugs, Vol. 10, Iss. 5, 2010-10 ,pp. :
Access to resources
Recommend
Controversy surrounding the safety of cerivastatin
Expert Opinion on Drug Safety, Vol. 1, Iss. 3, 2002-09 ,pp. :
Safety Assessment of an Anti-Obesity Drug (Sibutramine): A Retrospective Cohort Study
Drug Safety, Vol. 35, Iss. 8, 2012-08 ,pp. :
The Australian Therapeutic Goods Administration (TGA) is reviewing the safety of sibutramine
Reactions Weekly, Vol. 1, Iss. 1304, 2010-01 ,pp. :
The cardiovascular safety of rosiglitazone
By Ajjan Ramzi A Grant Peter J
Expert Opinion on Drug Safety, Vol. 7, Iss. 4, 2008-07 ,pp. :